Immunogenetic Background of Chronic Lymphoproliferative Disorders in Romanian Patients—Case Control Study
Medical Sciences · 2024
DOI: 10.3390/medsci12010014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Sciences, 2024. Verfasst von Maria Tizu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Immunology and Transplant Immunology, Carol Davila University of Medicine and Pharmacy, 258 Fundeni Avenue, 022328 Bucharest, Romania. Hauptthemen laut MEDLINE: Neoplasms, Lymphoproliferative Disorders. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objectives: The implications of the genetic component in the initiation and development of chronic lymphoproliferative disorders have been the subject of intense research efforts. Some of the most important genes involved in the occurrence and evolution of these pathologies are the HLA genes. The aim of this study is to analyze, for the first time, possible associations between chronic lymphoproliferative diseases and certain HLA alleles in the Romanian population. Materials and Methods: This study included 38 patients with chronic lymphoproliferative disorders, diagnosed between 2021 and 2022 at Fundeni Clinical Institute, Bucharest, Romania, and 50 healthy controls. HLA class I and class II genes (HLA-A/B/C, HLA-DQB1/DPB1/DRB1) were investigated by doing high resolution genotyping using sequence specific primers (SSP).
Results
Several HLA alleles were strongly associated with chronic lymphoproliferative disorders. The most important finding was that the HLA-C*02:02 (p = 0.002, OR = 1.101), and HLA-C*12:02 (p = 0.002, OR = 1.101) have a predisposing role in the development of chronic lymphoproliferative disorders. Moreover, we identified that HLA-A*11:01 (p = 0.01, OR = 0.16), HLA-B*35:02 (p = 0.037, OR = 0.94), HLA-B*81:01 (p = 0.037, OR = 0.94), HLA-C*07:02 (p = 0.036, OR = 0.34), HLA-DRB1*11:01 (p = 0.021, OR = 0.19), and HLA-DRB1*13:02 (p = 0.037, OR = 0.94), alleles have protective roles.
Conclusions
Our study indicates that HLA-C*02:02 and HLA-C*12:02 are positively associated with chronic lymphoproliferative disorders for our Romanian patients while HLA-DRB1*11:01, HLA-DRB1*13:02, and HLA-B*35:02 alleles have a protective role against these diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immunology and Transplant Immunology, Carol Davila University of Medicine and Pharmacy, 258 Fundeni Avenue, 022328 Bucharest, Romania.
- Centre of Immunogenetics and Virology, Fundeni Clinical Institute, 258 Fundeni Avenue, 022328 Bucharest, Romania.
- Academy of Romanian Scientists (AOSR), 3 Ilfov Street, Sector 5, 022328 Bucharest, Romania.
ORCID-Profile: Maria Tizu, Ion Maruntelu, Ileana Constantinescu
Zitieren
APA
Tizu, M., Calenic, B., Maruntelu, I., Caragea, A. M., Talangescu, A., Ursu, L., Rotarescu, C., Surugiu, M., Constantinescu, A. E., & Constantinescu, I. (2024). Immunogenetic Background of Chronic Lymphoproliferative Disorders in Romanian Patients—Case Control Study. Medical Sciences. https://doi.org/10.3390/medsci12010014
Vancouver
Tizu M, Calenic B, Maruntelu I, Caragea AM, Talangescu A, Ursu L, et al. Immunogenetic Background of Chronic Lymphoproliferative Disorders in Romanian Patients—Case Control Study. Medical Sciences. 2024. doi:10.3390/medsci12010014
BibTeX
@article{Tizu2024,
author = {Tizu, Maria and Calenic, Bogdan and Maruntelu, Ion and Caragea, Andreea Mirela and Talangescu, Adriana and Ursu, Larisa and Rotarescu, Corina and Surugiu, Mariana and Constantinescu, Alexandra Elena and Constantinescu, Ileana},
title = {Immunogenetic Background of Chronic Lymphoproliferative Disorders in Romanian Patients—Case Control Study},
journal = {Medical Sciences},
year = {2024},
doi = {10.3390/medsci12010014}
}
EUVIMED